{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+I&page=50",
    "query": {
      "condition": "Phase I",
      "page": 50
    },
    "page_size": 10
  },
  "pagination": {
    "page": 50,
    "page_size": 10,
    "total_count": 18748,
    "total_pages": 1875,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+I&page=51&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+I&page=49&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-12T06:29:20.428Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00546247",
      "title": "A Phase 1/2 Study of Epofolate (BMS-753493) in Subjects With Advanced Cancer (Schedule 1)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "Epofolate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2008-01",
      "completion_date": "2010-03",
      "has_results": false,
      "last_update_posted_date": "2015-10-12",
      "last_synced_at": "2026-11-12T06:29:20.428Z",
      "location_count": 3,
      "location_summary": "Washington D.C., District of Columbia • New York, New York • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00546247"
    },
    {
      "nct_id": "NCT00901849",
      "title": "Tarceva/Rapamycin for Children With Low-grade Gliomas With or Without Neurofibromatosis Type 1 (NF1)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Low-grade Gliomas"
      ],
      "interventions": [
        {
          "name": "Tarceva and Rapamycin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Roger Packer",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 21,
      "start_date": "2007-05",
      "completion_date": "2012-10",
      "has_results": false,
      "last_update_posted_date": "2014-09-16",
      "last_synced_at": "2026-11-12T06:29:20.428Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00901849"
    },
    {
      "nct_id": "NCT05141149",
      "title": "First in Human Phase1/2a Clinical Trial of Anti-PAUF Monoclonal Antibody PBP1510 in Patients With Pancreatic Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "PBP1510 (400mg/16mL)",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine (1000 mg/m^2)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Prestige Biopharma Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 80,
      "start_date": "2023-06-05",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-07-27",
      "last_synced_at": "2026-11-12T06:29:20.428Z",
      "location_count": 1,
      "location_summary": "New Hyde Park, New York",
      "locations": [
        {
          "city": "New Hyde Park",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05141149"
    },
    {
      "nct_id": "NCT04561258",
      "title": "Study to Evaluate the Safety of a Gene and Cell Therapy Product in Participants With HIV That is Well-Controlled on Antiretroviral Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV"
      ],
      "interventions": [
        {
          "name": "AGT103-T",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "American Gene Technologies International Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 7,
      "start_date": "2020-10-12",
      "completion_date": "2022-11-21",
      "has_results": false,
      "last_update_posted_date": "2023-04-12",
      "last_synced_at": "2026-11-12T06:29:20.428Z",
      "location_count": 2,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04561258"
    },
    {
      "nct_id": "NCT01032148",
      "title": "Study of LBH589, A Deacetylase Inhibitor in Patients With Recurrent or Refractory Hodgkin or Non-Hodgkin's Lymphoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hodgkin's Lymphoma",
        "Non-Hodgkin's Lymphoma"
      ],
      "interventions": [
        {
          "name": "LBH589",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2009-12",
      "completion_date": "2017-01",
      "has_results": false,
      "last_update_posted_date": "2017-01-12",
      "last_synced_at": "2026-11-12T06:29:20.428Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01032148"
    },
    {
      "nct_id": "NCT00405678",
      "title": "Exercise Intervention Study for Early-Stage Breast Cancer Patients Receiving Neoadjuvant Therapy.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Exercise Training",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Chemo only",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 23,
      "start_date": "2006-09",
      "completion_date": "2010-09",
      "has_results": false,
      "last_update_posted_date": "2014-07-11",
      "last_synced_at": "2026-11-12T06:29:20.428Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00405678"
    },
    {
      "nct_id": "NCT05124743",
      "title": "HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Ovarian Cancer",
        "Endometrial Cancer",
        "Colo-rectal Cancer",
        "Cholangiocarcinoma",
        "Non-small Cell Lung Cancer",
        "Pancreas Cancer"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Alaunos Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 19,
      "start_date": "2021-10-07",
      "completion_date": "2023-03-23",
      "has_results": false,
      "last_update_posted_date": "2026-10-15",
      "last_synced_at": "2026-11-12T06:29:20.428Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05124743"
    },
    {
      "nct_id": "NCT03598608",
      "title": "Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hodgkin Disease",
        "Lymphoma, Non-Hodgkin",
        "Lymphoma, B-Cell"
      ],
      "interventions": [
        {
          "name": "pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Favezelimab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 137,
      "start_date": "2018-10-17",
      "completion_date": "2026-01-28",
      "has_results": false,
      "last_update_posted_date": "2026-07-28",
      "last_synced_at": "2026-11-12T06:29:20.428Z",
      "location_count": 8,
      "location_summary": "Gilbert, Arizona • Duarte, California • Los Angeles, California + 5 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Monterey",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03598608"
    },
    {
      "nct_id": "NCT01753089",
      "title": "Dendritic Cell Activating Scaffold in Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "WDVAX",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2013-06",
      "completion_date": "2025-08-04",
      "has_results": false,
      "last_update_posted_date": "2025-09-15",
      "last_synced_at": "2026-11-12T06:29:20.428Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01753089"
    },
    {
      "nct_id": "NCT03036904",
      "title": "Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diffuse Large B-Cell Lymphoma",
        "High Grade B-Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Venetoclax",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Vincristine Sulfate",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin Hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Weill Medical College of Cornell University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 31,
      "start_date": "2017-02-06",
      "completion_date": "2021-11-11",
      "has_results": false,
      "last_update_posted_date": "2022-08-24",
      "last_synced_at": "2026-11-12T06:29:20.428Z",
      "location_count": 6,
      "location_summary": "Boston, Massachusetts • St Louis, Missouri • New York, New York + 3 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03036904"
    }
  ]
}